In adults with mild persistent asthma, is as-needed use of a combined inhaled corticosteroid plus long-acting beta-agonist as effective as scheduled use of an inhaled corticosteroid alone in preventing asthma exacerbations?

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Vishalakshi Sundaram ◽  
Linda Wei Zhang ◽  
Paige Gwynn
Keyword(s):  
Persistent Asthma ◽  
Beta Agonist ◽  
Inhaled Corticosteroid ◽  
Asthma Exacerbations ◽  
Mild Persistent Asthma ◽  
Long Acting

scholarly journals Predicting response to inhaled corticosteroid or long-acting muscarinic antagonist in mild persistent asthma

2020 ◽  
Vol 145 (2) ◽  
pp. AB338
Author(s):  
Jerry Krishnan ◽  
Stephen Lazarus ◽  
Kathryn Blake ◽  
Ronina Covar ◽  
Anne-Marie Dyer ◽  
...  
Keyword(s):  
Persistent Asthma ◽  
Inhaled Corticosteroid ◽  
Muscarinic Antagonist ◽  
Mild Persistent Asthma ◽  
Long Acting

scholarly journals Budesonide-Formoterol as Needed for The Treatment of Mild Persistent Asthma

2021 ◽  
Vol 2 (2) ◽  
Author(s):  
Emily B. Walsh ◽  
Alicia B. Forinash ◽  
Rebecca L. Stauffer ◽  
Abigail Yancey ◽  
Erica F. Crannage ◽  
...  
Keyword(s):  
Low Dose ◽  
Data Extraction ◽  
Symptom Control ◽  
Asthma Management ◽  
Persistent Asthma ◽  
Global Strategy ◽  
Beta Agonist ◽  
Mild Asthma ◽  
Inhaled Corticosteroid ◽  
Mild Persistent Asthma

Objective: To summarize literature assessing the safety and efficacy of budesonide/formoterol, a low dose inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) used as needed for the treatment of adult patients with mild persistent asthma requiring step 2 therapy compared to low dose inhaled corticosteroid (ICS) plus short-acting beta agonist (SABA) and SABA monotherapy. Data Sources: A literature search of PubMed (1966-October 2020), EMBASE (1973-October 2020) and clinicaltrials.gov was conducted using the following search terms: budesonide, formoterol, as needed, and mild asthma. Study selection and data extraction: Randomized, controlled trials with data describing as needed use of budesonide-formoterol in the treatment of mild, persistent asthma were included. Data synthesis: Current trials demonstrate a reduced risk of exacerbation and an improvement in symptom control in patients receiving budesonide/formoterol as needed when compared to as needed SABA alone. However, when compared to scheduled budesonide maintenance, patients receiving budesonide/formoterol as needed experienced worse symptom control and mixed exacerbation results. Relevance to patient care and clinical practice: This review evaluates the efficacy and safety of budesonide/formoterol as needed for patients with mild asthma. The Global Initiative for Asthma (GINA), a global strategy for asthma management and prevention adopted this change in 2019, and the most recent updated Expert Panel Report 4 of the National Asthma Education and Prevention Program (NAEPP) did not address this area. Conclusions: Based on this review of the literature, further study is needed to determine the place in therapy for budesonide/formoterol as needed in the treatment of mild persistent asthma. Low-dose ICS should remain the standard of therapy in patients with mild asthma requiring Step 2 therapy.

Sign in / Sign up

Export Citation Format

Share Document